Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and Adjuvant Targeted Therapy in BRAF V600 or MET Exon 14 NSCLC
NCT06054191Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib, capmatinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dabrafenib + trametinibtrametinibcapmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06054191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054191.